Menu
Neurogenesis is developing a cutting-edge approach to sustained delivery of unparalleled levels of remyelinating & regeneration proteins using the patient’s own stem cells. The NG CELL™ technology entails collecting bone marrow from the patient. Then by utilizing a proprietary process, a unique subpopulation of bone marrow cells is identified and enhanced to remyelinating & regenerating biofactory cells (NG Cells). The NG Cells are expanded to tens of millions and injected directly into the spinal cord fluid, home-in on the damaged area, take up residence for up to three months and produce sustained, massive amounts of remyelinating & neuronal growth proteins in order to in-situ remyelinate, regenerate and repair.
NG-01 is the company’s lead product, developed for the treatment of progressive multiple sclerosis and ALS. NG-01 cells have a remyelinating, neuroprotective and neuro regenerative properties. The cells can protect neurons and oligodendrocytes from apoptosis via the release of remyelination, regeneration and anti apoptotic molecules (CNTF, BDNF, and others), and have anti proliferative effects on microglial cells and astrocytes, resulting in the induction of a neuroprotective microenvironment. In recent studies, NG01 cells have also demonstrated the ability to promotes the proliferation and maturation of local neural precursor cells, leading to their differentiation into matureneurons and oligodendrocyt.
NG-02 is the company’s second product which is still under development. NG-02 cells have enhanced neuroprotective and neuro-regenerative properties and as demonstrated in preclinical studies, the potential to differentiate and acquire neuronal cell properties.
Intended indications for NG-02 are Parkinson’s disease, Alzheimer’s and other diseases of the central nervous system.